News & Events


ARMGO Pharma Discusses Results of RYR1-RM Phase 1b Trial of Rycal® ARM210 in Webinar by RYR1 Foundation
03.27.24
ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies
01.29.24
Join ARMGO at AHA Scientific Sessions, Philadelphia, USA, November 11 – 13, 2023
11.10.23
ARMGO presented at 23RD ANNUAL BIOTECH IN EUROPE FORUM in Basel, Switzerland, September 20 – 21, 2023
10.10.23
ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210 for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia
07.19.23
Join ARMGO at BIO International Convention, Boston, USA, June 05 – 08, 2023
05.05.23
Join ARMGO at 19th Orphan Drugs & Rare Disease Global Congress 2023, London, UK, April 3 – 4, 2023
03.31.23
Join ARMGO at Rare Disease Innovation & Partnership Summit in Philadelphia, USA, March 21 – 23, 2023
03.21.23
Join ARMGO at BIO-EUROPE in Leipzig, Germany, October 24 – 26, 2022
10.14.22